<DOC>
	<DOCNO>NCT01407003</DOCNO>
	<brief_summary>This study ass safety , tolerability , effect LIK066 blood glucose healthy subject patient T2DM .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics ( PK ) Pharmacodynamics ( PD ) Assessment LIK066 Healthy Subjects Patients With Type 2 Diabetes Mellitus ( T2DM )</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Parts I III : Healthy male female subject age 18 55 year age include , good health determine past medical history , physical examination , electrocardiogram , laboratory test screen . Parts II IV : Patients , age 1865 year , must diagnose T2DM least 8 week prior screen HbA1c 6.5 10.0 % , inclusive , screen . Fasting plasma glucose â‰¤250mg/dL screening baseline . If treat metformin , patient must stable dose 12 week prior randomization maintain dose end study . Exclusion Criteria ; part : Patients type 1 diabetes mellitus . Patients history acute diabetic complication within 6 month prior screen . Women childbearing potential . Patients sign symptom significant diabetic complication . Patients treat certain blood pressure lipid lower medication unless patient stable dos 12 week prior dose . History drug alcohol abuse within 12 month prior dose . Any surgical medical condition , acute unstable chronic disease may , base investigator 's opinion , jeopardize patient case participation study . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>T2DM , blood glucose , OGTT , LIK066</keyword>
</DOC>